Dr Reddy’s Q4 Result: Pharma company Dr Reddy’s profits have fallen by about 28 per cent year-on-year in the fourth quarter of FY 2021. During this time the company has made a profit of Rs 554 crore. Whereas the company had a profit of Rs 764 crore in the same quarter of the last financial year. However, the company’s revenue has increased during this period. The board of the pharma company has announced a dividend of Rs 25 per share to shareholders at a face value of Rs 5 for FY 2021.
Q4FY21: Revenue up by 7%
In the fourth quarter of FY 2021, Dr. Reddy’s revenue has been 7%. The company’s revenue during this period has been Rs 4728 crores. At the same time, the company’s revenue in the fourth quarter of the last financial year was Rs 4432 crore.
EBITDA margin stood at 24 per cent in the fourth quarter, while the company’s margin stood at 22.6 per cent in the fourth quarter of the previous financial year. The EBITDA of the company during this period has been Rs 1133 crore. Whereas the EBITDA of the company stood at Rs 1001 crore in the fourth quarter of last year.
Indian business strong
The company’s North America business income decreased 3 percent year-on-year. At the same time, PSAI business has seen a growth of 10 percent. During this period, the Indian business income of the company grew by 23 per cent on an annual basis. The company’s European business income has increased 15 per cent year-on-year. Income of global generics business increased by 6 percent on an annual basis.
Increase in productivity
GV Prasad, co-chairman and MD of Dr. Reddy’s Lab said that in FY 2021 we have continued to strengthen all our businesses, increase productivity and strengthen our development pipeline. The company is prioritizing its efforts to launch the Sputnik V vaccine across India, working on the development and commercialization of several drugs to treat mild to severe COVID 19 infections.